About 182,835 results

ALLMedicine™ Lung Cancer Center

Research & Reviews  52,654 results

Robot-assisted thoracic surgery for stages IIB-IVA non-small cell lung cancer: retrospe...
Journal of Robotic Surgery; Shahin GMM, Vos PWK et. al.

Mar 18th, 2023 - Robot-assisted thoracic surgery (RATS) for higher stages non-small cell lung carcinoma (NSCLC) remains controversial. This study reports the feasibility of RATS in patients with stages IIB-IVA NSCLC. A single-institute, retrospective study was con...

A longitudinal circulating tumor DNA-based model associated with survival in metastatic...
Nature Medicine; Assaf ZJF, Zou W et. al.

Mar 18th, 2023 - One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been sma...

Advancing neoadjuvant immunotherapy for lung cancer.
Nature Medicine; Conroy M, Forde PM

Mar 18th, 2023 - Advancing neoadjuvant immunotherapy for lung cancer.|2023|Conroy M,Forde PM,|

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-smal...
Nature Medicine; Cascone T, Leung CH et. al.

Mar 18th, 2023 - Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvan...

Radionuclide-based theranostics - a promising strategy for lung cancer.
European Journal of Nuclear Medicine and Molecular Imaging; Zhu T, Hsu JC et. al.

Mar 18th, 2023 - This review aims to provide a comprehensive overview of the latest literature on personalized lung cancer management using different ligands and radionuclide-based tumor-targeting agents. Lung cancer is the leading cause of cancer-related deaths w...

see more →

Guidelines  99 results

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideli...
Annals of Oncology : Official Journal of the European Soc... Hendriks LE, Kerr KM et. al.

Mar 6th, 2023 - Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.|2023|Hendriks LE,Kerr KM,Menis J,Mok TS,Nestle U,|

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Gui...
Annals of Oncology : Official Journal of the European Soc... Hendriks LE, Kerr KM et. al.

Jan 21st, 2023 - Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.|2023|Hendriks LE,Kerr KM,Menis J,Mok TS,Nestle U,|

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Gu...
Journal of Clinical Oncology : Official Journal of the Am... Singh N, Temin S et. al.

Jul 12th, 2022 - To provide evidence-based recommendations updating the 2021 ASCO and Ontario Health (Cancer Care Ontario) guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC) with driver alterations. ASCO updated recommendat...

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Journal of Clinical Oncology : Official Journal of the Am... Daly ME, Singh N et. al.

Dec 23rd, 2021 - To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, communit...

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JN... Ganti AKP, Loo BW et. al.

Dec 14th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment...

see more →

Drugs  246 results see all →

Clinicaltrials.gov  7,464 results

A Study of SEA-CD40 Given With Other Drugs in Cancers

Mar 10th, 2023 - This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial. In one part, participan...

Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

Mar 10th, 2023 - Lung cancer accounts for 30% of all cancers among American war Veterans and remains the leading cause of cancer related deaths. Half of all lung cancers are metastatic non-small cell lung cancer (NSCLC), with a 2-year survival rate of 10%. Immunot...

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable St...

Mar 10th, 2023 - PRIMARY OBJECTIVE: I. To evaluate whether there is an improvement in overall survival with concomitant chemotherapy/radiation therapy/MEDI4736 (durvalumab) followed by one year (12 cycles) of MEDI4736 (durvalumab) as compared to concomitant chemot...

Digital Outreach Intervention for Lung Cancer Screening

Mar 10th, 2023 - Primary Objective: Determine the effectiveness of mPATH-Lung on receipt of LCS in a randomized pragmatic clinical trial of 1318 patients recruited from two large health networks, Wake Forest Baptist Health and the University of North Carolina at C...

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Mar 10th, 2023 - The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.

see more →

News  12,574 results

Shortage of Prostate Cancer Drug; Win for DBT Mammo; Double Lung Transplant

Mar 16th, 2023 - Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is currently in shortage, according to the FDA, leaving some prostate cancer patients with limited options; the drug's manufacturer Novartis said it's working to increase production. Meanwhile, the ...

FDA Allows Lower Risk Designation for Snuff Product

Mar 16th, 2023 - The FDA authorized the U.S. Smokeless Tobacco Company, a subsidiary of tobacco giant Altria, to market Copenhagen Classic Snuff as less likely to cause lung cancer than cigarettes. The loose moist snuff smokeless tobacco product had already been o...

Introducing CHEST President-Designate John A. Howington, MD, MBA, FCCP

Mar 10th, 2023 - John A. Howington, MD, MBA, FCCP, is a cardiothoracic surgeon currently serving as Chief of Oncology Services and Chair of Thoracic Surgery at Ascension Saint Thomas Health and a professor at the University of Tennessee Health Sciences Center in N.

Jimmy Carter's Melanoma; Post-Op Osimertinib Boosts OS; $83K for Unproven Therapy

Mar 9th, 2023 - How the successful use of pembrolizumab (Keytruda) for former President Jimmy Carter's metastatic melanoma put "immunotherapy on the map." (Washington Post) A study of molecular changes observed in the breast tissue of transgender men undergoing a...

'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advances

Mar 3rd, 2023 - The verbiage surrounding a person's experience with cancer or some other serious illness, particularly references to "battle," has the unintended effect of portraying survivors as "winners" and those who die as "losers." (NPR) The annual cost of n...

see more →

Patient Education  97 results see all →